EUVIMEDEUVIMED entdecken
Crossref

Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a‐rearranged acute myeloid leukemia

Lulu Wang, Yuxiu Chen, Mengtong Zang, Jianying Zhou, Mengyu Xiao, Haixia Fu, Xiaodong Mo, Fengrong Wang, Wei Han, Yuanyuan Zhang, Chenhua Yan, Zhidong Wang und 11 weitere

Cancer · 15.01.2025 · 131 (2)

DOI: 10.1002/cncr.35717 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 06.01.2025. Verfasst von Lulu Wang und 22 weiteren Autor:innen. Beteiligte Einrichtung: Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Neoplasm, Residual, Leukemia, Myeloid, Acute, Histone-Lysine N-Methyltransferase, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of Beijing Municipality, Key Program of National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with lysine methyltransferase 2a ( KMT2A )‐rearranged ( KMT2A ‐r) acute myeloid leukemia (AML) are assigned to intermediate‐risk and adverse‐risk categories at diagnosis. However, the value of molecular measurable residual disease (MRD) status in patients who have KMT2A ‐r AML before allogeneic hematopoietic stem cell transplantation (allo‐HSCT) in adult cohorts has rarely been evaluated.

Methods

Patients with KMT2A ‐r AML who achieved complete remission and subsequently underwent allo‐HSCT between January 2015 and January 2023 were included in this analysis. Real‐time quantitative polymerase chain reaction was used to detect molecular MRD in bone marrow samples. The end points were overall survival (OS), leukemia‐free survival (LFS), the cumulative incidence of relapse (CIR), and nonrelapse mortality (NRM).

Results

Pretransplantation molecular MRD was identified in 52 of 125 patients (42%) with KMT2A ‐r AML. The presence of KMT2A ‐r MRD was associated with inferior 3‐year OS (51% vs. 82%; p < .001), LFS (42% vs. 81%; p < .001), CIR (33% vs. 12%; p < .001), and NRM (11% vs. 5%; p = .12). In multivariate models, molecular MRD status before transplantation independently predicted OS, LFS, and CIR. The survival of adult patients with KMT2A ‐r AML was heterogeneous, depending on the KMT2A translocation partners, and was more favorable in patients who had t(9;11) and t(10;11) than in those who had t(11;19) and t(6;11). In addition, flow cytometry‐based MRD analysis conferred no additional prognostic value to the results of molecular MRD status.

Conclusions

Residual KMT2A ‐r before allo‐HSCT independently predicts the risk of survival and relapse, and donor lymphocyte infusion or posttransplantation maintenance therapies should be considered for patients who have AML with detectable molecular MRD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm, ResidualLeukemia, Myeloid, AcuteHistone-Lysine N-MethyltransferaseHematopoietic Stem Cell TransplantationMyeloid-Lymphoid Leukemia ProteinHumansFemaleMaleAdultMiddle AgedYoung AdultAgedTransplantation, HomologousPrognosisAdolescentGene RearrangementRecurrenceNeoplasm Recurrence, Local

Stichwörter der Autor:innen

acute myeloid leukemiaallogeneic hematopoietic stem cell transplantationlysine methyltransferase 2a (KMT2A)measurable residual diseaserearrangement

Substanzen

Histone-Lysine N-MethyltransferaseMyeloid-Lymphoid Leukemia ProteinKMT2A protein, human

Autor:innen und Institutionen

  • Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
  • National Clinical Research Center for Hematologic Disease, Beijing, China.
  • Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Collaborative Innovation Center of Hematology, Peking University, Beijing, China.

ORCID-Profile: Xiaohui Zhang

Förderung

  • National Key Research and Development Program of China
  • Natural Science Foundation of Beijing Municipality
  • Key Program of National Natural Science Foundation of China
  • Capital Health Research and Development of Special Fund

Zitieren

APA

Wang, L., Chen, Y., Zang, M., Zhou, J., Xiao, M., Fu, H., Mo, X., Wang, F., Han, W., Zhang, Y., Yan, C., Wang, Z., Han, T., Lv, M., Chen, H., Chen, Y., Chen, Y., Wang, J., Wang, Y., …, & Zhang, X. (2025). Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a‐rearranged acute myeloid leukemia. Cancer, 131(2). https://doi.org/10.1002/cncr.35717

Vancouver

Wang L, Chen Y, Zang M, Zhou J, Xiao M, Fu H, et al. Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a‐rearranged acute myeloid leukemia. Cancer. 2025;131(2). doi:10.1002/cncr.35717

BibTeX
@article{Wang2025,
  author = {Wang, Lulu and Chen, Yuxiu and Zang, Mengtong and Zhou, Jianying and Xiao, Mengyu and Fu, Haixia and Mo, Xiaodong and Wang, Fengrong and Han, Wei and Zhang, Yuanyuan and Yan, Chenhua and Wang, Zhidong and Han, Tingting and Lv, Meng and Chen, Huan and Chen, Yuhong and Chen, Yao and Wang, Jingzhi and Wang, Yu and Xu, Lanping and Liu, Kaiyan and Huang, Xiaojun and Zhang, Xiaohui},
  title = {Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a‐rearranged acute myeloid leukemia},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {2},
  doi = {10.1002/cncr.35717}
}
Kostenlos starten →